期刊
ARCHIVES OF MEDICAL RESEARCH
卷 45, 期 7, 页码 580-588出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.arcmed.2014.11.002
关键词
Hepatocellular carcinoma; Serum; Glypican-3; Diagnostic accuracy
资金
- Key Research Project of Tianjin Health Bureau [11KG112]
Background and Aims. The diagnostic value of serum GPC3 in patients with hepatocellular carcinoma (HCC) remains controversial. Thus, we performed a systematic review and meta-analysis to assess the diagnostic accuracy of serum GPC3 for HCC. Methods. A systematic search was performed for the related studies. Sensitivity, specificity and other measures regarding the accuracy of serum GPC3 and alpha-fetoprotein (AFP) in the diagnosis of HCC were pooled using random-effects models. Summary receiver operating characteristic curve (sROC) analysis was used to summarize the overall test performance. Results. Nineteen studies were included in this meta-analysis. Pooled sensitivity, specificity and 95% confidence interval (CI) of serum GPC3 for the diagnosis of HCC were 55.2% (52.9-57.4%) and 84.2% (82.2-86.0%), respectively. When combining GPC3 with APP, pooled sensitivity, specificity, and 95% CI were 75.7% (71.8-79.4%) and 83.3% (79.6-86.6%), respectively. The area under sROC (AUC) and 95% CI for AFP combined with GPC3 were 0.762 (0.649-0.875). For diagnosis of early HCC, pooled sensitivity and specificity of serum GPC3 were 55.1% (47.9-66.2%) and 97.0% (95.2-98.2%), respectively. The AUC of GPC3 for early HCC was 0.793 (0.668-0.917). Conclusions. This meta-analysis indicates that serum GPC3 has a comparable accuracy to APP for the diagnosis of HCC, and there is an elevation in the sensitivity of diagnosis when GPC3 was combined with APP. Diagnostic accuracy of serum GPC3 for early HCC is still unsatisfactory. (C) 2014 IMSS. Published by Elsevier Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据